Details for Patent: 10,322,139

Which drugs does patent 10,322,139 protect, and when does it expire?

Patent 10,322,139 protects ZULRESSO and is included in one NDA.

This patent has forty-five patent family members in twenty-four countries.

Summary for Patent: 10,322,139

Title:	Neuroactive steroid formulations and methods of treating CNS disorders
Abstract:	Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a .beta.-cyclodextrin, e.g., a sulfo butyl ether .beta.-cyclodextrin, e.g., a .beta.-cyclodextrin, e.g., a sulfo butyl ether .beta.-cyclodextrin, e.g., CAPTISOL.RTM.; and methods of use in treating CNS disorders.
Inventor(s):	Reddy; Kiran (Boston, MA)
Assignee:	Sage Therapeutics, Inc. (Cambridge, MA)
Application Number:	15/649,583
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 10,322,139

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		RX	Yes	Yes			Y

International Family Members for US Patent 10,322,139

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013212287
Australia	2018201307
Australia	2020217402
Brazil	112014018110
Canada	2862076
China	104736158